Press Release Details

Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September

08/29/18 at 7:00 AM EDT

HOUSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in two upcoming healthcare investor conferences.

Conference Details:

Event: Citi’s 13th Annual Biotech Conference
Date: Wednesday, September 5, 2018
Location: Boston, MA

Event: 2018 Wells Fargo Securities Healthcare Conference
Date/Time: Thursday, September 6, 2018 at 10:55 a.m. EDT
Location: Boston, MA

A live webcast of the presentation at Wells Fargo may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at

Source: Bellicum Pharmaceuticals

Solebury Trout
Chad Rubin

Solebury Trout
Brad Miles

Primary Logo

Source: Bellicum Pharmaceuticals, Inc.